Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis

Mohamed Sayed Zaazouee, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
Asmaa Gomaa Alwarraqi, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Yasmine Adel Mohammed, Faculty of Medicine, Assiut University, Assiut, Egypt.
Mohamed A. Badheeb, College of Medicine, Hadhramout University, Al-Mukalla, Yemen.Follow
Abdullah Mohamed Farhat, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Mohammed Eleyan, Department of Laboratory Medical Sciences, Alaqsa University, Gaza, Palestine.
Afnan Morad, Faculty of Medicine, Assiut University, Assiut, Egypt.
Marwa Abdel-Aziz Zeid, Clinical Pharmacist, Pediatrics Department, Ministry of Health, Qalyubia, Egypt.
Aya Shaban Mohamed, Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Hazem AbuEl-Enien, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt.
Ahmed Abdelalim, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Ahmed Bostamy Elsnhory, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Yasmin S. Hrizat, Faculty of Medicine, University of Jordan, Amman, Jordan.
Nagat Taha Altahir, Faculty of Nursing, Khartoum University, Khartoum, Sudan.
Doaa Atef, Department of Emergency Medicine, Assiut University, Assiut, Egypt.
Alaa Ahmed Elshanbary, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Khalaf F. Alsharif, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Khalid J. Alzahrani, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Mohammad Algahtani, Department of Laboratory and Blood Bank, Security Forces Hospital, Mecca, Saudi Arabia.
Abdulrahman Theyab, Department of Laboratory and Blood Bank, Security Forces Hospital, Mecca, Saudi Arabia.
Yousef M. Hawsawi, College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia.
Ahmed A. Aldarmahi, Basic Science Department, College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, National Guard-Health Affairs, Jeddah, Saudi Arabia.
Mohamed M. Abdel-Daim, Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia.

Document Type

Article

Publication Title

Frontiers in pharmacology

Abstract

Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor and inhibits the signaling of IL-4 and IL-13. It is approved for treating asthma and other type-2 inflammatory diseases. There is a conflict in the literature regarding the safety and efficacy of dupilumab. Thus, we aimed to assess the safety and efficacy of dupilumab in patients with moderate to severe asthma. Six databases (PubMed, Embase, Scopus, Web of Science, Cochrane library, and clinicaltrials.gov registry) were searched until January 2022. We included randomized controlled trials that compared dupilumab with the placebo in moderate to severe asthma patients. We extracted the data at 12 and 24 weeks and analyzed them using review manager 5.4. Thirteen trials were included. Dupilumab significantly improved the forced expiratory volume in 1 s, asthma control questionnaire score, the fraction of exhaled nitric oxide level, and immunoglobulin E level at 12 and 24 weeks (p < 0.05). However, it was associated with increased blood eosinophils at 12 and 24 weeks. Dupilumab was generally a safe agent for asthmatic patients. It showed no significant difference compared with the placebo regarding most adverse events. Dupilumab improves pulmonary function and reduces local and systemic inflammatory markers with minimal adverse events in patients with moderate to severe asthma.

First Page

992731

DOI

10.3389/fphar.2022.992731

Publication Date

1-1-2022

Identifier

36263132 (pubmed); PMC9574251 (pmc); 10.3389/fphar.2022.992731 (doi); 992731 (pii)

This document is currently not available here.

Share

COinS